Bassline Productions
Baseline Productions, Inc. does not have significant operations. Previously, the company focused on developing immunotherapeutic based technology related to cancer indication. The company was founded in 2010 and is based in Scottsdale, Arizona.
Bassline Productions (BSSP) - Net Assets
Latest net assets as of September 2015: $-862.05K USD
Based on the latest financial reports, Bassline Productions (BSSP) has net assets worth $-862.05K USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.95K) and total liabilities ($873.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-862.05K |
| % of Total Assets | -7871.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bassline Productions - Net Assets Trend (2011–2014)
This chart illustrates how Bassline Productions's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bassline Productions (2011–2014)
The table below shows the annual net assets of Bassline Productions from 2011 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-407.61K | -230.03% |
| 2013-12-31 | $-123.51K | -481.67% |
| 2012-12-31 | $-21.23K | +72.13% |
| 2011-12-31 | $-76.18K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bassline Productions's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67816300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | % |
| Other Components | $358.80K | % |
| Total Equity | $-407.61K | 100.00% |
Bassline Productions Competitors by Market Cap
The table below lists competitors of Bassline Productions ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gourmet Provisions International Corp
PINK:GMPR
|
$0.90 |
|
Axiologix Inc
PINK:AXLX
|
$0.90 |
|
North American Exploration Corp
OTCGREY:NAMX
|
$0.90 |
|
1812 Brewing Company Inc
PINK:KEGS
|
$0.90 |
|
Emp Solutons Inc
PINK:EMPS
|
$0.90 |
|
China Industrial Waste Management Inc
PINK:CIWT
|
$0.90 |
|
Mid-Atlantic Home Health Network Inc
PINK:MAHN
|
$0.90 |
|
Fuelstream Inc
PINK:FLST
|
$0.90 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bassline Productions's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -123,507 to -407,605, a change of -284,098.
- Net loss of 441,369 reduced equity.
- Other factors increased equity by 157,271.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-441.37K | -108.28% |
| Other Changes | $157.27K | +38.58% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Bassline Productions's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bassline Productions utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-84.10K |
| 2012 | 0.00% | -402.80% | 30.93x | 0.00x | $-46.21K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-176.11K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-400.61K |
Industry Comparison
This section compares Bassline Productions's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bassline Productions (BSSP) | $-862.05K | 0.00% | N/A | $0.90 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |